Browse by author
Lookup NU author(s): Dr Miguel Lopez-Lazaro,
Professor Caroline AustinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Digitoxin is used in the treatment of cardiac congestion and some types of cardiac arrhythmias. The mechanism of action of this cardiac glycoside suggested that it might antagonize the anticancer activity of topoisomerase II poisons. The present report shows that digitoxin, at concentrations commonly found in the plasma of cardiac patients, significantly reduced etoposide and idarubicin-induced topoisomerase II cleavable complexes in K562 leukemia cells. This may lead to a reduction in the anticancer effect of these two topoisomerase II poisons when they are used in the clinic concurrently with digitoxin. © 2005 Elsevier Ltd. All rights reserved.
Author(s): Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Cortes F, Austin CA
Publication type: Article
Publication status: Published
Journal: Leukemia Research
ISSN (print): 0145-2126
ISSN (electronic): 1873-5835
PubMed id: 16387358
Altmetrics provided by Altmetric